ARTELO BIOSCIENCES, INC. filed a Form D with the Securities and Exchange Commission on 2026-02-06.
ARTELO BIOSCIENCES, INC. filed a Form D notice of an exempt securities offering with the SEC on February 6, 2026. The filing reports $500K sold. Its industry group is Biotechnology. It names Gregory Gorgas (Executive Officer, Director), Connie Matsui (Director), Douglas Blayney (Director) (SEC Form D, February 6, 2026).
Sell to companies like ARTELO BIOSCIENCES, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-02-06 · the record
Pitching, partnering or investing alongside them? See who really runs and owns ARTELO BIOSCIENCES, INC.
Free to see. No signup.
More on the people and the money behind ARTELO BIOSCIENCES, INC., from the filings we hold.
Biotechnology raises by companies based in California, filed in February 2026, largest first.
Get an email when ARTELO BIOSCIENCES, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when ARTELO BIOSCIENCES, INC. raises, hires or launches. No email unless you switch it on.
Watch ARTELO BIOSCIENCES, INC. →Get the full cited report on ARTELO BIOSCIENCES, INC.
What the filing shows about ARTELO BIOSCIENCES, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ARTELO BIOSCIENCES, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for ARTELO BIOSCIENCES, INC. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on ARTELO BIOSCIENCES, INC. See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $500K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Gregory Gorgas is named as Executive Officer and Director on the Form D that ARTELO BIOSCIENCES, INC. filed with the SEC on 6 February 2026, one of 8 people that filing names.
Connie Matsui is named as Director on the Form D that ARTELO BIOSCIENCES, INC. filed with the SEC on 6 February 2026, one of 8 people that filing names.
Douglas Blayney is named as Director on the Form D that ARTELO BIOSCIENCES, INC. filed with the SEC on 6 February 2026, one of 8 people that filing names.
Steven Kelly is named as Director on the Form D that ARTELO BIOSCIENCES, INC. filed with the SEC on 6 February 2026, one of 8 people that filing names.
R. Emanuele is named as Director on the Form D that ARTELO BIOSCIENCES, INC. filed with the SEC on 6 February 2026, one of 8 people that filing names.
Tamara Favorito is named as Director on the Form D that ARTELO BIOSCIENCES, INC. filed with the SEC on 6 February 2026, one of 8 people that filing names.
Gregory Reyes is named as Director on the Form D that ARTELO BIOSCIENCES, INC. filed with the SEC on 6 February 2026, one of 8 people that filing names.
Mark Spring is named as Executive Officer on the Form D that ARTELO BIOSCIENCES, INC. filed with the SEC on 6 February 2026, one of 8 people that filing names.
8 people named on the filing — 2 holding an executive role and 6 as directors only.
Named as of the 2026-02-06 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about ARTELO BIOSCIENCES, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ARTELO BIOSCIENCES, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ARTELO BIOSCIENCES, INC. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist ARTELO BIOSCIENCES, INC.You get an alert in MentionFox the next time this company shows up.
If you're behind ARTELO BIOSCIENCES, INC.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for ARTELO BIOSCIENCES, INC.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Diego
https://mentionfox.com/funding/artelo-biosciences-inc-form-d-26000005